BMHCA (Butylphenyl Methylpropional)

Butylphenyl Methylpropional, also known under various trade names and synonyms including Lilial® and Lysmeral® CAS No. 80-54-6In February 2019 the ECHA RAC concluded that re-classification as a CMR reprotox 1B (H360F) was justified.

The new classification has been incorporated into CLP legislation via ATP 15 which was adopted by the European Commission on 19th May 2020 and published in the Official Journal on 11th August 2020 with an application date of 1st March 2022.

From this date

BMHCA will be banned in cosmetic products (new and on-shelf)
BMHCA will be banned in household products (consumer) containing equal or more than 0.3% (not classified as Rep 1B)

BMHCA may be placed on the market and used in products sold for professional use containing equal or more than 0.3% (classified as Rep 1B). In this case the packaging of such substances and mixtures must be marked visibly, legibly and indelibly as ‘Restricted to professional uses’ on top of the CLP labelling.

The above-mentioned regulatory events and activities are limited to those products manufactured and sold within the EU & UK.

As a note:- Sweden has sent an Annex XV dossier to ECHA proposing to identify BMHCA as a Substances of Very High Concern (SVHC) and once a substance is identified as an SVHC, it would be added to the Candidate List for inclusion in the Authorisation List. BMHCA was identified as a SVHC and added to the Candidate List on July 8th, 2021. The public consultation on ECHA’s draft recommendation typically runs once every one to one and a half years. Based on the experience with other substances, we could expect the public consultation for BMHCA to start in 2023, but it could be earlier. If no authorisation application is submitted, this will ban the use of BMHCA in all applications.

Our website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.